Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. MPLT | 0.00 |
Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:
MPLT) with a Buy rating and announces Price Target of $43.
